
Cognition Therapeutics Receives Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Listing: Company Details
Cognition Therapeutics Receives Notice from Nasdaq: What Does This Mean for the Company and the Investors? On September 12, 2024, Cognition Therapeutics, Inc. (CGTX) received a notification from the Nasdaq Stock Market LLC that the bid price of its common stock had closed below $1.00 per share for 30 consecutive business days. This triggered a…